Table 6. Safety profiles of values and percentage changes from baseline after 12 weeks of treatment with pitavastatin or atorvastatin.

	Baseline	Week 12	Percentage change (%)#	Baseline vs. week 12 p-value
hsCRP [mg/dL]
PTV	0.17 ± 0.2	0.14 ± 0.21	−28.6 ± 157.4	0.08
ATV	0.33 ± 1.1	0.19 ± 0.38	−10.8 ± 124.9	0.38
CPK [U/L]
PTV	125.4 ± 64.6	153.2 ± 252.7	22.3 ± 140.6	0.13
ATV	130.9 ± 81.1	142.7 ± 90.8	17.8 ± 45.8	0.0001
AST [U/L]
PTV	27.5 ± 10.7	28.3 ± 13.6	5.9 ± 29.3	0.05
ATV	26.8 ± 7.1	27.4 ± 8.5	4.5 ± 24.9	0.07
ALT [U/L]
PTV	31.5 ± 17.9	32.1 ± 19.5	6.7 ± 33.8	0.06
ATV	30.6 ± 15.1	31.1 ± 14.3	10.5 ± 39.9	0.008
Gamma GT [U/L]
PTV	37.6 ± 37	34.8 ± 25.6	−5.6 ± 29.9	0.07
ATV	36.8 ± 27.5	37. ± 27.1	6.2 ± 32.3	0.05
Total bilirubin [mg/dL]**
PTV	0.8 ± 0.3	0.7 ± 0.3	−0.9 ± 31.8	0.77
ATV	0.8 ± 0.3	0.9 ± 0.4	14.0 ± 43.0	0.001
BUN [mg/dL]
PTV	15.7 ± 3.6	16.4 ± 4.0	5.2 ± 22.0	0.02
ATV	15.7 ± 3.9	16.1 ± 4.5	4.2 ± 19.8	0.03
Serum creatinine [mg/dL]
PTV	0.8 ± 0.2	0.8 ± 0.2	−1.2 ± 9.9	0.24
ATV	0.8 ± 0.2	0.8 ± 0.2	−0.7 ± 10.7	0.54
LDH [U/L]
PTV	192.0 ± 31.7	189.7 ± 33.8	−0.3 ± 14.6	0.84
ATV	193.8 ± 38.4	195.3 ± 47.7	1.3 ± 17.9	0.45

Data are means ± standard deviation. Abbreviations and units: (see Tables 1 & 2). # Values are ([value at 12 weeks − value at baseline]/[value at baseline]). ** Values were significantly different between the PTV and ATV groups.